Atrial Fibrillation: Epidemiologic Considerations and Rationale for Conversion and Maintenance of Sinus Rhythm
Open Access
- 1 March 2003
- journal article
- research article
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 8 (1_suppl), S13-S26
- https://doi.org/10.1177/107424840300800103
Abstract
Atrial fibrillation is now the most common cardiac arrhythmia for which a patient is hospitalized. Clinically, it presents in a form that is paroxysmal, persistent, or permanent and may be symptomatic or asymptomatic, occurring in the setting of either no cardiac disease (“lone atrial fibrillation”) or, most often, in association with an underlying disease. Atrial fibrillation is associated with a 2-fold increase in mortality and, in the United States alone, causes over 75,000 cases of stroke per year. The annual prevalence of stroke is 5% to 7%, but the use of adequate anticoagulation can reduce this to less than 1%. Atrial fibrillation is a disorder of the elderly, with almost equal prevalence in men and women. In the United States, 80% of atrial fibrillation occurs in patients over the age of 65 years, and its prevalence tracks that of heart failure, which may be the cause, as well as the result, of the arrhythmia. Both conditions are increasing in epidemic proportions in the aging population. The most common causes of atrial fibrillation are hypertensive heart disease, coronary artery disease, and heart failure with a miscellany of lesser conditions, with about 10% lacking structural heart disease. Unlike other supraventricular arrhythmias, cure by the use of catheter ablation and surgical techniques has not been a reality except in a relatively small number of cases. However, restoration and maintenance of sinus rhythm remain the initial goal of therapy for most patients. Pharmacologic approaches remain the mainstay of therapy for rate control and anticoagulation as well as for maintenance of sinus rhythm following pharmacological or electrical conversion. The changing epidemiology of atrial fibrillation is highlighted, with the focus on its conversion by the use of newer and novel antifibrillatory agents relative to the mechanisms of the arrhythmia, to restore the stability of sinus rhythm.Keywords
This publication has 55 references indexed in Scilit:
- Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overviewEP Europace, 2000
- Tachycardia-Related Cardiomyopathy: A Common Cause of Ventricular Dysfunction in Patients With Atrial Fibrillation Referred for Atrioventricular AblationMayo Clinic Proceedings, 2000
- Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available.The American Journal of Cardiology, 1998
- Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic AgentCardiovascular Drug Reviews, 1997
- Secular trends in the prevalence of atrial fibrillation: The Framingham studyAmerican Heart Journal, 1996
- Use-Dependent Effects of the Class III Antiarrhythmic Agent NE-10064 (Azimilide) on Cardiac RepolarizationJournal of Cardiovascular Pharmacology, 1995
- Divergent effects of chronic amiodarone administration on systolic and diastolic function in patients with heart diseaseThe American Journal of Cardiology, 1995
- Protection Against Programmed Electrical Stimulation-Induced Ventricular Tachycardia and Sudden Cardiac Death by NE-10064, a Class III Antiarrhythmic DrugJournal of Cardiovascular Pharmacology, 1993
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- The Natural History of Lone Atrial FibrillationNew England Journal of Medicine, 1987